Imatinib-responsive hypereosinophilia in a patient with B cell ALL

Leuk Lymphoma. 2004 Dec;45(12):2497-501. doi: 10.1080/10428190400005288.

Abstract

Hypereosinophilia is a rare presenting sign of acute lymphocytic leukemia. A 29-year-old male was diagnosed with idiopathic hypereosinophilic syndrome with respiratory symptoms. Although his peripheral blood eosinophilia decreased in response to treatment with imatinib mesylate, a follow-up bone marrow showed a diffuse infiltrate of myeloperoxidase-negative blasts. He was subsequently diagnosed with CD10 positive precursor B lymphoblastic leukemia. This case underscores the importance of follow-up bone marrow examination in patients who demonstrate imatinib mesylate-responsive eosinophilia.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Benzamides
  • Burkitt Lymphoma / complications*
  • Burkitt Lymphoma / drug therapy*
  • Burkitt Lymphoma / pathology
  • Eosinophils / pathology
  • Humans
  • Hypereosinophilic Syndrome / complications*
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / pathology
  • Imatinib Mesylate
  • Leukocyte Count
  • Male
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate